Regulaxis SAS, was founded on the basis of 15 years of research at the CNRS and with a capital "love money" twenty some former associates entrepreuneurs in the life sciences. JEI since its inception (2013) it develops in three major areas, regenerative medicine, growth dysfonction and oncology, synthetic peptides that regulate cell growth and differentiation and whose patents are its property. The first program of R&D aims to develop a drug for early knee osteoarthritis therapy (KOA). KOA concerns 30% of people 65 years but can concern also younger, as a consequence of injuries due to sport, overweight, obesity. In two years Regulaxis was / winner "emergence" of the National Competition 2013 Ministry of Research / ranked in the top 15 start-up of the international competition "Innovation's Days" / called to represent, as startup, excellence collaboration France-Israel in 2014 by supporting Israel the President of the Republic / classified in December 2014 in 100 start-ups in which to invest in France in the ranking prepared by the weekly "Challenge's" / winner "creation-development" of the National Competition ILab 2015 Ministry of Research and BPI / the same year (2015) Regulaxis was also awarded the prestigious European competition in the EMS program H2020 Phase 1.